Claudin 18.2—a FAST-moving target in gastric cancer?
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference17 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet (Lond, Engl),2010
3. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer;Shitara;N Engl J Med,2020
4. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study;Moehler;Ann Oncol,2020
5. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin;Furuse;J Cell Biol,1998
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse;Journal of Pharmaceutical and Biomedical Analysis;2024-08
2. Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer;Frontiers in Oncology;2024-06-14
3. High Expression of CLDN 18.2 is Associated with Poor Disease-Free Survival of HER-2 Positive Gastric Cancer;International Journal of General Medicine;2024-04
4. Construction of a Human Immune Library from Gallbladder Cancer Patients for the Single-Chain Fragment Variable (scFv) Antibody Selection against Claudin 18.2 via Phage Display;Antibodies;2024-03-12
5. Claudins and hepatocellular carcinoma;Biomedicine & Pharmacotherapy;2024-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3